European Journal of Cancer
Volume 38 , Pages S7-S12 , December 2002

Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval

  • M.E. Gore

      Affiliations

    • Medical Oncology, Royal Marsden Hospital NHS Trust, London, UK
    • Tel.: +44-0207-808-2198; Fax: +44-207-808-2475.
    • ,
  • R.J. Atkinson

      Affiliations

    • Department of Oncology, Belfast City Hospital, Belfast, N. Ireland
    • ,
  • H. Thomas

      Affiliations

    • The Royal Surrey Hospital, Guildford, UK
    • ,
  • H. Cure

      Affiliations

    • CAC Jean Perrin, Clermont Ferrand, France
    • ,
  • D. Rischin

      Affiliations

    • Peter McCallum Cancer Institute, St Andrews Place, East Melbourne, Australia
    • ,
  • P. Beale

      Affiliations

    • Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    • ,
  • P. Bougnoux

      Affiliations

    • CHU Hospital Bretonneau, Tours, France
    • ,
  • L. Dirix

      Affiliations

    • Oncologisch Centrum, Oosterveldlaan, Wilrijk, Belgium
    • ,
  • W.M. Smit

      Affiliations

    • Medisch Spectrum Twente, Enschede, the Netherlands

References 

  1. Conte PF, Cianci C, Tanganelli L, Gadducci A. Ovarian cancer: optimal therapy in relapsed disease. Ann Oncol. 2000;11:145–150
  2. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer. 1998;77:366–373
  3. Akiyama S-I, Chen Z-S, Sumizawa T, Furukawa T. Resistance to cisplatin. Anticancer Drug Design. 1999;8:143–151
  4. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–211
  5. Markman M, Rothman R, Hakes T, et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393
  6. Ozols RF. Update of the NCCN ovarian cancer guidelines. Oncology. 1997;11:95–105
  7. Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol. 2001;12:1195–1203
  8. Medina-Gundrum L, Gomez L, Cerna C, et al.  ZD0473 exhibits marked in vitro antitumour activity in human tumour specimens. Eur J Cancer. 2001;37:454; (abstr)
  9. Raynaud FI, Boxall FE, Goddard PM, et al.  cis-Amminedichloro(2-methylpyridine)platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res. 1997;3:2063–2074
  10. Akiyama Y, Kusaba H, Kanzawa F, Tamura T, Saijo N, Nishio K. Overcoming cisplatin-resistance by ZD0473 (cis-amminedichloro[2-methylpyridine]platinum[II]) in human lung cancer cells. In: Poster presented at the 2nd International Lung Cancer Conference. Hawaii. July 18–21, 2001;
  11. Kelland L, Judson I, Koehler M, Stephens T, Roberts D. Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro [2-methylpyridine] platinum [II]). Lung Cancer. 2000;70:227; (abstr)
  12. Gore ME, Atkinson RJ, Thomas H, et al.  A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer. 2002; In Press
  13. Canetta R, Bragman K, Smaldone L, Rozencweig M. Carboplatin: current status and future prospects. Cancer Treat Rev. 1988;15(Suppl B):17–32
  14. Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer CA, Morris M. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol. 1989;73:798–802
  15. Kjorstad K, Harris A, Bertelsen K, et al.  A multicentre phase II study of carboplatin in advanced ovarian carcinoma: final report. Ann Oncol. 1992;3:217–222
  16. National Cancer Institute PDQ Statement . Ovarian epithelial cancer (PDQ): treatment - health professional. January 2002;
  17. McGuire WP, Rowinsky EK, Rosenshein NB, et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian neoplasms. Ann Intern Med. 1989;111:273–279
  18. Kohn EC, Sarosy G, Bicher A, et al.  Dose-intensive taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994;86:18–24
  19. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy: a Gynaecologi Oncology Group study. J Clin Oncol. 1994;12:1748–1753
  20. Muggia FM, Hainsworth JD, Jeffers S, et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987–993
  21. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecam. J Clin Oncol. 2001;19:3312–3322
  22. ten Bokkel Huinink W, Gore M, Carmichael J, et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–2193
  23. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynaecologic Oncology Group study. J Clin Oncol. 1998;16:405–410
  24. Bajetta E, Leo AD, Biganzoli L, et al.  Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum resistant disease. J Clin Oncol. 1996;14:2546–2551
  25. Gatzemeier U, Twelves C, Anthoney DA, Pentheroudakis G, Groth G, Cosaert J. A phase I dose-escalation study of ZD0473 combined with paclitaxel in refractory solid malignancies. Eur J Cancer. 2001;37:264; (abstr)
  26. Dizon DS, Maluf F, Aghajanian C, et al.  Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumour malignancies. Eur J Cancer. 2001;37:273; (abstr)

PII: S0959-8049(02)80014-4

European Journal of Cancer
Volume 38 , Pages S7-S12 , December 2002

Article Tools